Close Menu

NEW YORK – Natera said on Monday that it has sued ArcherDx, alleging infringement of a recently issued patent covering target amplification.

In its complaint, filed with the US District Court of Delaware, San Carlos, California-based Natera said that ArcherDx, based in Boulder, Colorado, infringes its US Patent No. 10,538,814 titled "Methods for Simultaneous Amplification of Target Loci." The patent, issued on Jan. 21, covers methods that use multiplex PCR to amplify several nucleic acid regions in the same reaction for sequencing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.